Revenue YoY
+9.93%
Operating Income YoY
+35.53%
Net Income YoY
+33.70%
Net Margin Δ
+306 bps
Net income bridge for AstraZeneca (AZN) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: $2.62B+33.70%
Profit bridge breakdown for AstraZeneca (AZN) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | $7.77B | — |
| Revenue | $5.46B | +208.5% |
| Cost of Revenue | −$840.00M | -32.1% |
| Operating Expenses | −$864.00M | -33.0% |
| Other Income / Expense | −$132.00M | -5.0% |
| Income Tax | −$1.01B | -38.6% |
| Net Income | $10.39B | — |
- Prior Net Income$7.77B
- Revenue$5.46B
- Cost of Revenue−$840.00M
- Operating Expenses−$864.00M
- Other Income / Expense−$132.00M
- Income Tax−$1.01B
- Net Income$10.39B
Identity residual: $6.00M (delta between driver sum and reported ΔNI)
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement